The Biotech Chronicle | Leading Biotech's Evolution & : Stories https://biotechchronicle.com/rss/category/stories The Biotech Chronicle | Leading Biotech's Evolution & : Stories en Copyright © 2023 The Biotech Chronicle. All Rights Reserved. Singapore's Biotech Odyssey: 20 Years In Search of Global Recognition https://biotechchronicle.com/singapores-biotech-odyssey-20-years-in-search-of-global-recognition https://biotechchronicle.com/singapores-biotech-odyssey-20-years-in-search-of-global-recognition Tue, 07 Nov 2023 18:33:49 +0600 admin Singapore biotech, Biomedical science, Biotech hub, Biopharma companies, Hummingbird Bioscience, Tessa Therapeutics, Success stories, Drug development, Government initiatives, Global recognition, Biotech investments, Clinical-stage biotech, Cell and gene therapies, ASTAR, Biotech talent pool, Pharma investment, U.S.-China relationship, Singapore's biotech industry, Geopolitical tension, Innovation fellowship, Biotech managers, Southeast Asia, Pharmaceutical investments, Economic development

In the year 2000, Singapore charted a visionary course in the realm of biomedical science, designating it a key pillar of its economy. This commitment materialized in the establishment of Biopolis in 2003, a bespoke biomedical R&D hub. Substantial financial investments flowed into the life sciences sector, attracting a multitude of biopharma enterprises. Despite these efforts, Singapore has yet to carve its niche as a globally recognized player in the biotech arena.

Challenges and Setbacks: The biotech landscape has witnessed setbacks, notably with Aslan Pharmaceuticals' lead drug failure in a midstage trial in 2019 and the unexpected shutdown of Tessa Therapeutics, despite amassing over $200 million in funding. Aum Biosciences added to the concerns by terminating a SPAC deal in June, casting a shadow on investor confidence.

The Litmus Test: Private investors, initially cautious, now demand tangible success stories. While isolated victories, such as CTI Biopharma's FDA-approved JAK inhibitor Vonjo, exist, broader acknowledgment proves elusive.

Current Landscape: Amid the challenges, Hummingbird Bioscience emerges as a potential success story, securing a significant $125 million in funding in 2021. Aslan Pharmaceuticals persists with its eczema candidate eblasakimab. However, Singapore, boasting 52 biotechs, faces a talent shortage and stiff competition from established hubs like Boston.

Government Initiatives: The Agency for Science, Technology and Research (A*STAR) plays a pivotal role, fostering research capabilities through collaborations with renowned global universities. Government funding, unwavering political support, and initiatives like Create underscore Singapore's commitment to its biotech ambition.

Talent Development and Challenges: Singapore grapples with a shallow talent pool, prompting collaborations with global programs like Stanford Biodesign. Bridging the gap in experienced biotech leadership remains a priority for sustained industry growth.

Global Dynamics: Singapore's strategic location and political neutrality continue to attract foreign pharma investments. Heightened geopolitical tensions between the U.S. and China further fuel pharmaceutical investments, with companies like Sanofi, BioNTech, and Merck expanding their footprint in the region.

Looking Ahead: Acknowledging its uniqueness, Singapore sets its sights on a specialized role. Focusing on nucleic acid therapeutics, bioprocessing, and cell and gene therapies, the nation adapts to global dynamics while navigating its path in the biotech landscape.

In conclusion, Singapore's biotech journey persists, marked by challenges, talent acquisition endeavors, and a relentless pursuit of global recognition. The next five years hold promise for the emergence of success stories that will define Singapore's role in the ever-evolving biotech ecosystem.

]]> EggLogics' Breakthrough Technologies Revolutionize IVF Success Rates A Game&Changer in Fertility Science https://biotechchronicle.com/egglogics-breakthrough-technologies-revolutionize-ivf-success-rates-a-game-changer-in-fertility-science https://biotechchronicle.com/egglogics-breakthrough-technologies-revolutionize-ivf-success-rates-a-game-changer-in-fertility-science Mon, 12 Jul 2021 04:14:04 +0600 admin EggLogics, IVF technology, Fertility breakthrough, EggBoost, EggCheck, In-vitro fertilization, Biotech start-up, Women's health, Clinical trials, Hong Kong, Global market, HKTDC, Entrepreneurship, Gene-based technology, Reproductive outcomes, Bioinformatics, Artificial intelligence, Medical devices, Pre A-round financing, Start-up Express, Dr. Lee Tin-lap, Asia Financial Forum, Healthcare innovation, Science Park, Cyberport In the realm of reproductive technology, EggLogics emerges as a game-changer, spearheading a revolution in in-vitro fertilization (IVF) with their cutting-edge advancements. Driven by the mission to enhance IVF success rates, particularly for women aged 35 and above, EggLogics’ groundbreaking proprietary technologies promise a significant transformation in egg quality and fertility outcomes.

EggLogics' Vision and Innovation:

Founded by Dr. Lee Tin-lap, a former Professor at the Chinese University of Hong Kong, EggLogics champions a novel approach centered on optimizing egg health. Leveraging a fusion of clinical science, regenerative biomedicine, genomics, bioinformatics, and biomedical engineering, the company introduces three proprietary technologies: EggBoost, EggCheck, and a micro-microscopy device.

EggBoost: Enhancing Egg Quality and Quantity:

EggBoost, the flagship technology, aims to enrich and mature eggs, promoting their quality and quantity for improved reproductive outcomes. Utilizing innovative chips and a specialized culture medium, this non-invasive technique shows promise not only in IVF treatments but also in egg freezing, offering hope for women seeking fertility options.

EggCheck: Precision in Egg Quality Assessment:

Another breakthrough, EggCheck, employs precise gene information for accurate assessment, assisting women and clinicians in identifying viable eggs for IVF or egg freezing. This gene-based technology introduces a simplified grading rubric, facilitating informed decisions in reproductive procedures.

Advancements and Clinical Trials:

EggLogics has transitioned its pioneering developments from laboratory confines to real-world applications. Collaborating with the Prince of Wales Hospital in Shatin, preliminary human studies have commenced, ensuring safety and soliciting feedback from IVF clients. The company gears up for expansive clinical trials across multiple centers, targeting regulatory approvals in China and the United States.

Global Expansion and Recognition:

With a market estimated at US$14 billion annually, EggLogics eyes global opportunities. Engaging with clinical research organizations associated with regulatory bodies in China and the US, the company navigates the path toward approvals and trials, poised to revolutionize fertility treatments on a larger scale.

EggLogics' Entrepreneurial Journey and Collaborations:

EggLogics' journey epitomizes a transition from academia to entrepreneurship, emphasizing open-mindedness and public engagement. The company's collaborations and recognitions, including the HKTDC Start-up Express program, have been instrumental in forging connections, securing funding, and expanding their reach internationally.

Looking Ahead:

As EggLogics strides towards clinical trials and global market penetration, collaborations with IVF clinics in Southeast Asia and partnerships with life science labs in Boston further underscore the company's commitment to advancing women's reproductive health worldwide.

Conclusion:

EggLogics stands at the forefront of a paradigm shift in reproductive technology, poised to redefine the landscape of fertility treatments. With its pioneering innovations and strategic collaborations, the company charts a trajectory toward empowering women and reshaping the future of IVF.

]]>